SAB Biotherapeutics

11:15 AM - 11:30 AM (EST), Monday, February 6, 2023 ・ Winter Garden
SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development of proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases, immune and autoimmune disorders and oncology. Our development programs harness the body’s natural defense system to address infectious diseases resulting from outbreaks and pandemics, as well as immunological, gastroenterological, and respiratory diseases that have significant mortality and health impacts on immunocompromised patients. SAB’s novel drug development platform, DiversitAb™, has the capability to generate large quantities of specifically targeted, high-potency polyclonal antibodies without the need for convalescent plasma or human donors. We have optimized and advanced genetic engineering and antibody science to develop Transchromosomic cows (Tc Bovine™) that produce fully-human, highly-efficacious polyclonal antibodies. The Tc Bovine™ are a proprietary component of our platform.
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
South Dakota
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
Pan Influenza: SAB-176
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Co-Founder, President & CEO
SAB Biotherapeutics